证券代码：688046 证券简称：药康生物 公告编号：2025-060 江苏集萃药康生物科技股份有限公司 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 江苏集萃药康生物科技股份有限公司（以下简称"公司"）第二届董事会第十 三次会议于 2025 年 8 月 21 日现场结合通讯的方式召开。本次会议的通知已于 会董事 9 人，实际出席董事 9 人，其中独立董事 3 人，公司监事、高级管理人员 列席了会议。本次会议的召集、召开符合《中华人民共和国公司法》（以下简称 《公司法》）等法律法规及《江苏集萃药康生物科技股份有限公司章程》（以下简 称《公司章程》）的相关规定。 二、董事会会议审议情况 （一）审议通过《关于公司2025年半年度报告及其摘要的议案》 董事会认为，公司 2025 年半年度报告及摘要的编制和审议程序符合法律法规、 《公司章程》和公司内部管理制度的各项规定，公允地反映了公司 2025 年半年度 的财务状况和经营成果等事项，所披露的信息真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 ...

证券代码：600426 证券简称：华鲁恒升 编号：临 2025-042 山东华鲁恒升化工股份有限公司 第九届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东华鲁恒升化工股份有限公司第九届董事会第六次会议于 2025 年 8 月 21 日在公司 会议室以现场加通讯方式举行，本次会议的召开通知已于 2025 年 8 月 11 日以通讯方式下 发，应参会董事 11 名，实际参会董事 11 名，其中：庄光山先生、吴非先生以视频方式参 会。会议召开符合《公司法》等相关法律法规的规定，会议形成的决议合法、有效。经与 会董事审议投票表决，通过了以下决议： 一、审议通过《关于公司 2025 年半年度报告的议案》。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 此项议案事前已经公司董事会审计委员会表决同意：公司严格按照《公司章程》、《会 计法》和上市公司信息披露的有关规定进行了 2025 年半年度报告的编制，各项数据真实 地反映了公司财务状况和经营成果，各项分析客观地反映了公司的生产经营状况。202 ...

证券代码：600717 证券简称：天津港 公告编号：临 2025-020 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 一、董事会召开情况 公司十一届一次董事会于2025年8月21日以现场会议结合视频会 议方式召开，现场会议在天津港办公楼403会议室召开。会议通知于 名，实际出席董事9名。独立董事侯欣一、曹强先生以视频方式参会。 公司高管人员列席了本次会议。会议由公司董事长刘庆顺先生主持。 会议的通知、召开、表决程序符合法律、法规、规范性文件及《公司 章程》的规定，会议合法有效。 二、董事会审议情况 本议案事前经公司十一届一次董事会审计委员会审议通过。 同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司于 2025 年 8 月 23 日披露的《天津港股份有限 公司 2025 年半年度报告》 本议案事前经公司十一届一次董事会审计委员会审议通过。 具体内容详见公司于 2025 年 8 月 23 日披露的《天津港股份有限 公司 2025 年半年度报告摘要》 同意 9 票，反对 0 票，弃权 0 票。 续评估报告》 本议 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-060 上海奥浦迈生物科技股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第十一次会议于2025年8月21日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月11日送达全体董事。本次会议由董事长 肖志华先生召集并主持，会议应出席董事7名，实际出席董事7名，本次会议的召 集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法有效。 二、董事会会议审议情况 表决结果：7票同意、0票反对、0票弃权；获全体董事一致通过。 具体内容详见公司于同日刊载于上海证券交易所网站（www.sse.com.cn）的 《上海奥浦迈生物科技股份有限公司2025年半年度报告》及《上海奥浦迈生物科 技股份有限公司2025年半年度报告摘要》。 上述议案在提交董事会审议前已经审计委员会 ...

Core Viewpoint - The company is committed to enhancing its core business and competitiveness through increased R&D investment and operational efficiency, while also focusing on investor returns and sustainable growth [1][5][6] Group 1: Business Focus and R&D Investment - The company specializes in cell culture products and services, aiming to provide comprehensive solutions for the biopharmaceutical industry [1] - R&D investment has consistently exceeded 10% of annual revenue, with a focus on developing proprietary technologies and expanding product lines [11][10] - The company has developed multiple new cell culture media products, enhancing its competitive edge in therapeutic protein production [12][13] Group 2: Financial Performance and Market Expansion - The sales revenue from cell culture products increased by 25.49% year-on-year, driven by the steady progress of client pipelines and rapid overseas expansion [2] - The company served over 700 domestic and international biopharmaceutical enterprises and research institutions, solidifying its market position [2][10] - The CDMO service business also showed positive growth, with a revenue increase of 13.24% compared to the previous year [2] Group 3: Investor Relations and Return Mechanisms - The company maintains a stable cash dividend policy, distributing a total of 22,709,750.80 yuan in cash dividends for the 2025 mid-year [5][6] - A share repurchase plan was completed, with a total transaction amount of 50,998,163.75 yuan, aimed at enhancing long-term investment value [7][8] - The company plans to implement a mid-year profit distribution of 2.30 yuan per share, amounting to 26,116,213.42 yuan, which represents 69.56% of the net profit for the first half of 2025 [6] Group 4: Internal Management and Quality Control - The company has successfully passed ISO9001:2015 quality management system audits, demonstrating its commitment to high-quality standards [16] - Continuous improvement in internal control systems and governance structures is prioritized to enhance operational efficiency and risk management [19][20] - The company emphasizes talent development, with over 70% of R&D personnel holding master's or doctoral degrees, fostering a strong innovation culture [17][18] Group 5: Future Outlook and Strategic Initiatives - The company is actively pursuing a major asset restructuring to enhance operational quality and risk resilience [17][18] - Plans to explore various share repurchase methods to strengthen capital structure and enhance investor value are in place [8] - The company aims to expand its international market presence while continuously optimizing product offerings and service quality [15][16]

株洲时代新材料科技股份有限公司 半年度评估报告 株洲时代新材料科技股份有限公司（以下简称"时代新材"、 "公 司"）积极响应上海证券交易所《关于开展沪市公司"提质增效重回 报"专项行动的倡议》，制定了《2025 年度"提质增效重回报"行 动方案》（以下简称"行动方案"），切实履行"提高上市公司质量、 增强投资者回报、提升投资者获得感"的应尽之责。现对该行动方案 的半年度实施情况进行评估，具体如下： 一、聚焦战略性新兴产业，稳步提升经营质量 公司围绕中国中车加快构建轨道交通装备和清洁能源装备"双赛 道双集群"产业发展新格局，以"一核三极多点"为牵引，以"稳中 求进、品质发展"为发展思路，以"深化改革、创新引领、深耕细作、 全球经营、严控风险"为经营方针，是中国中车战略新兴产业发展的 使命担当者。 （一）提升销售回报率 公司产能布局不断优化，产能效率持续提升。完善风电叶片产业 布局，持续提升叶片制造规模效应，西北、蒙西二期工厂日产能平均 提升 3.5 支，推进海外越南工厂建设，新设铁岭生产基地，全年叶片 交付产值提升 38%，全员人均产值提升 20.66%，持续保持行业领先地 位。完成轨道交通产业创新中心智能制造 ...

Core Points - The board of directors of CITIC Heavy Industries convened its 14th meeting of the 6th session on August 22, 2025, to discuss various important matters [2][3] - The meeting was attended by all 7 directors, and all resolutions were passed unanimously [2] Financial Reports - The board approved the "2025 Half-Year Report" and its summary, which had been reviewed by the audit committee [2] - A special report on the use of raised funds was also approved, detailing the storage and actual usage of these funds [3] Action Plans and Evaluations - The board reviewed and approved the evaluation report on the implementation of the "Quality Improvement and Efficiency Enhancement" action plan for the first half of 2025 [2][3] - A proposal to use part of the idle raised funds for cash management and to store the remaining funds in agreed deposits was also approved [3] Project Adjustments - The board approved a proposal to re-evaluate and temporarily suspend certain investment projects funded by raised capital [3] Risk Assessment - A continuous risk assessment report regarding CITIC Financial Co., Ltd. was approved, with certain directors abstaining from the vote [3][4] ESG and Market Value Management - The board approved the establishment of an "ESG Management System" in accordance with various legal and regulatory guidelines [4][5] - A proposal to create a "Market Value Management System" was also approved, aligning with relevant laws and the company's actual situation [5]

Meeting Overview - The board meeting of Fujian Haitong Development Co., Ltd. was held on August 20, 2025, with all 7 directors present, ensuring compliance with legal and regulatory requirements [1]. Resolutions Passed Stock Repurchase and Cancellation - The board approved the repurchase and cancellation of a total of 302,600 restricted stocks and 164,000 stock options due to the departure of certain incentive targets and performance issues [1][2]. Stock Option and Restricted Stock Incentive Plan - The board confirmed that the conditions for the first exercise period of the 2024 stock option and restricted stock incentive plan have been met, allowing 13 eligible individuals to exercise a total of 345,000 stock options [2][3]. Release of Restricted Stocks - The board acknowledged that the conditions for the second release period of the 2023 restricted stock incentive plan have been fulfilled, allowing 38 individuals to apply for the release of 1,336,440 restricted stocks, which represents 0.14% of the company's total share capital [3][4]. Quality Improvement Action Plan - The board reviewed and approved the evaluation report of the "Quality Improvement and Return to Shareholders" special action plan for the first half of 2025, which aligns with national economic directives and aims to enhance the company's development and investment value [4][5]. Organizational Structure Adjustment - The board approved adjustments to the company's organizational structure to improve operational efficiency and governance, authorizing management to implement these changes [5].

Core Viewpoint - The company has implemented a "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on strengthening its core business, optimizing production capacity, and enhancing market competitiveness while maintaining investor interests [1][8]. Group 1: Business Performance and Strategy - In the first half of 2025, the company achieved a net profit attributable to shareholders of -9.0573 million yuan, a reduction in loss by 3.8239 million yuan compared to the same period last year, indicating a 29.69% improvement in loss narrowing [1]. - The company has successfully implemented a price increase strategy for its photoinitiator products, leading to a slight profit in Q2 2025 and an overall positive operational trend [1]. - The company has completed the development of 29 semiconductor g-line and i-line photoresist products, with 13 successfully introduced to the market, indicating strong market acceptance [3]. Group 2: Production and Capacity Optimization - The company has optimized the use of 50 million yuan of previously unutilized fundraising to support the H4 ketone project at its subsidiary, enhancing production efficiency and self-sufficiency in key intermediates [2]. - The overall capacity utilization rate of the company's subsidiary in Inner Mongolia has significantly improved, with several products reaching or nearing design capacity [2]. - The company is advancing digital capabilities, including the launch of an AI-driven customer service system to enhance response speed and resource allocation [3]. Group 3: Innovation and Product Development - The company holds 192 patents, including 128 invention patents, and has developed a range of macromolecular products, with significant sales in UV LED photoinitiators and cationic photoinitiators [5]. - The company has established a project database to track customer needs and provide comprehensive solutions, enhancing its market promotion efforts [5]. - An internal innovation competition has been held to stimulate employee creativity, with rewards provided to winning teams to encourage ongoing innovation [6]. Group 4: Governance and Compliance - The company is enhancing its internal governance structure and compliance awareness among key personnel through targeted training sessions [7]. - A special task force has been established to revise internal control systems, ensuring compliance and effective governance [7]. - The company has been recognized as a "Green Supply Chain Management Enterprise" for its commitment to sustainable development and carbon reduction initiatives [7]. Group 5: Investor Relations and Communication - The company emphasizes investor relations, conducting multiple communication initiatives, including a performance briefing and interactive Q&A sessions, achieving a 100% response rate to investor inquiries [8]. - The company has utilized new media platforms to enhance communication with investors, publishing 27 articles to keep them informed [8]. - Continuous evaluation of the action plan will be conducted to ensure alignment with investor interests and market expectations [8].

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-064 湖北济川药业股份有限公司 第十届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）本次会议的召开符合《公司法》《公司章程》《董事会议事规则》的 规定。 （二）本次会议通知和相关资料于 2025 年 8 月 12 日以书面方式送达全体董 事和监事。 （三）本次会议于 2025 年 8 月 22 日在湖北济川药业股份有限公司（以下简 称"公司"）办公大楼十楼会议室以现场及通讯表决的方式召开。 （四）本次会议应参加董事 7 人，实际参加董事 7 人，其中独立董事姚宏先 生、卢超军先生、杨玉海先生以通讯方式出席会议。 （五）本次会议由董事长曹龙祥先生召集和主持，公司全体监事及高级管理 人员列席会议。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告全文及摘要的议案》 同意 7 票，反对 0 票，弃权 0 票。本议案获得通过。 （三）审议通过《关于 2024 年度"提质增效重回报" ...